Trevi Therapeutics (TRVI) Q1 2026 earnings review
Cash Secured to 2030, Now the Waiting Game Begins
Trevi has removed its biggest existential threat by raising $162 million in April, extending its cash runway into 2030. With FDA alignment secured for the Phase 3 IPF-related chronic cough program, the focus shifts entirely to execution. Research and development expenses are accelerating (up 27% YoY to $9.9M) as four major trials spin up. The catch? The first pivotal Phase 3 readout for the lead IPF indication won't arrive until H1 2028. Investors must now endure a two-year catalyst desert, relying on secondary indication readouts to maintain momentum.
🐂 Bull Case
The $162M April raise extends the cash runway into 2030, fully funding the Haduvio pipeline through potential FDA approval. Management no longer has to execute under the threat of a binary financing event.
Following a successful End-of-Phase 2 meeting, the FDA is fully aligned on the clinical development plan for Haduvio in IPF-related chronic cough, removing major regulatory uncertainty.
🐻 Bear Case
Topline data for the first pivotal Phase 3 IPF trial is slated for H1 2028. This extended timeline tests investor patience and leaves the stock vulnerable to macro drift.
The massive $162M capital raise significantly dilutes existing shareholders. The weighted average share count was already accelerating, hitting 145.6M in Q1 before this new offering.
⚖️ Verdict: ⚪
Neutral. Securing cash through 2030 is a massive fundamental victory for a clinical-stage biotech. However, the heavy shareholder dilution and a multi-year wait for pivotal IPF data cap the near-term upside.
Key Themes
Capital Overhang Eliminated
The April 2026 underwritten offering netted ~$162 million, drastically changing the company's financial profile. This moves the cash runway from 'into 2028' to 'into 2030,' giving Trevi the absolute balance sheet security to run two Phase 3 IPF trials and two Phase 2b trials simultaneously without returning to the capital markets.
Timeline to Key Data Extends to 2028
While management previously touted strong momentum following positive Phase 2 data, the actual timeline to pivotal data is sobering. Trial 1 for Phase 3 IPF will initiate in Q2 2026 but won't read out until H1 2028 due to FDA requirements for 52 weeks of fixed dosing. This contradicts the narrative of an immediate 'inflection point' and requires investors to hold through a multi-year execution phase.
Broadening the Addressable Market
Trevi is aggressively moving to expand Haduvio's total addressable market (TAM). While IPF presents a 140,000 U.S. patient market, the planned Phase 2b trials in non-IPF ILD and Refractory Chronic Cough (RCC) open doors to 228,000 and 2-3 million U.S. patients, respectively. This transforms Haduvio from a niche orphan drug into a potential blockbuster platform.
Accelerating G&A and R&D Spend
Net loss widened to $13.2M (from $10.3M a year ago). G&A specifically jumped 36% to $5.0M, driven by intellectual property legal fees and headcount. As the company transitions into running four major clinical trials globally, investors should expect R&D spend to aggressively accelerate in the coming quarters. The cash is there, but the burn rate will look formidable.
Intellectual Property Fortress
The company received a notice to grant a European patent covering nalbuphine ER (Haduvio) for the treatment of IPF-related chronic cough, with an expected expiration in 2039. This builds a strong moat around the lead asset in a critical global market.
Other KPIs
Derived by combining the Q1 ending balance of $171.8M with the $162M net proceeds from the April 2026 offering. This war chest fully funds Haduvio's development for IPF-related chronic cough potentially through FDA approval, mitigating all near-term financing risks.
Accelerating significantly. The share count was 117.6M in 25Q1, rose steadily through 2025, and hit 145.6M in 26Q1. Importantly, this Q1 figure does not fully capture the dilution from the $162M April 2026 offering, meaning Q2 2026 will show another massive step-up in outstanding shares.
Guidance
Accelerating. The company updated its runway guidance from 'Into 2028' to 'Into 2030' following the April capital raise. This includes funding Phase 2b and Phase 3 trials across all three chronic cough indications.
Management expects Trial 1 topline data in H1 2028, and Trial 2 topline data in H2 2027. The staggered readouts are due to Trial 1's longer 52-week fixed dosing requirement for safety.
This trial features an adaptive design with a sample size re-estimation (SSRE) analysis expected in Q4 2026, making it the nearest-term milestone. Topline results are expected in H2 2027.
Key Questions
Interim Look at RCC Data
The Phase 2b RCC trial includes a sample size re-estimation (SSRE) in Q4 2026. Will this purely be a blinded operational update, or will investors get any directional efficacy color from this milestone?
Enrollment Execution
The Phase 3 IPF trials are heavily dependent on site activation. What is the specific site activation ramp, and how quickly must you enroll patients to hit the H2 2027 and H1 2028 data readout timelines?
Commercial Expense Modeling
You noted the cash runway does not include commercial expenses related to a launch. At what point in the 2028-2030 timeline will Trevi begin deploying capital toward a commercial salesforce infrastructure?